NCT06156579View on ClinicalTrials.gov

Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML

PHASE2RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

November 4, 2023

Primary Completion Date

September 1, 2026

Study Completion Date

March 31, 2027

Conditions
AMLMDS
Interventions
DRUG

Decitabine

Decitabine 20 mg/m\^2, i.v., once daily, 10 days

DRUG

Venetoclax

Venetoclax, 400 mg, p.o., once daily, 28 days

Trial Locations (1)

72076

RECRUITING

University Hospital, Tübingen

All Listed Sponsors
lead

University Hospital Tuebingen

OTHER